Lon­za un­veils new ex­pan­sion plans at Swiss man­u­fac­tur­ing sites, cap­ping off a very busy pan­dem­ic

Lon­za will ex­pand its drug de­vel­op­ment in Switzer­land yet again with in­vest­ments in three of its man­u­fac­tur­ing sites, the com­pa­ny an­nounced Wednes­day, cap­ping off a very busy year for the Eu­ro gi­ant.

The ex­pan­sion will fea­ture the ad­di­tion of an asep­tic fill­ing line for clin­i­cal sup­ply of drug prod­ucts in Stein, as well as ad­di­tions to sup­port both clin­i­cal and com­mer­cial man­u­fac­tur­ing at Basel and Visp.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN